[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 30, 1973

Antitussives in Jeopardy

Author Affiliations

American Medical Association Chicago

JAMA. 1973;224(5):621-622. doi:10.1001/jama.1973.03220180041012

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In the Federal Register, Feb 9, 1973, the Food and Drug Administration (FDA) published a notice to withdraw from the market certain antitussive combinations. Named in the withdrawal notice are the following preparations:

Novrad With ASA

Coricidin With Codeine Phosphate

Phenergan Expectorant With Codeine

Phenergan Expectorant

Phenergan VC Expectorant

Phenergan VC Expectorant With Codeine

Pediatric Phenergan Expectorant

Phenergan Expectorant Troches

Phenergan Expectorant Troches With Codeine

Dimetane Expectorant

Dimetane Expectorant-DC

Omni-Tuss suspension

Tussionex tablets

Ulogesic tablets

Ulominic Syrup

Coditrate Syrup

Methajade liquid

Thephorin Expectorant

Actifed-C Expectorant

Clistin Expectorant

Tuss-Ornade liquid

Tuss-Ornade Spansules

Benylin Expectorant

Ambenyl Expectorant

Cothera Compound

Pyribenzamine Expectorant

Pyribenzamine Expectorant With Codeine and Ephedrine

However, other products of similar compositions will also be affected even though they are not specifically cited.

The FDA is basing this action on regulations established by the 1962 Harris-Kefauver amendments to the Food, Drug, and Cosmetic Act of 1938 and on the National Academy